Global Trust Asset Management LLC Cuts Stock Position in AbbVie Inc. $ABBV

Global Trust Asset Management LLC decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 75.4% in the fourth quarter, HoldingsChannel reports. The fund owned 785 shares of the company’s stock after selling 2,409 shares during the quarter. Global Trust Asset Management LLC’s holdings in AbbVie were worth $179,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ABBV. Brighton Jones LLC grew its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. raised its stake in AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after buying an additional 789 shares during the last quarter. 1832 Asset Management L.P. boosted its holdings in AbbVie by 158.7% in the second quarter. 1832 Asset Management L.P. now owns 20,590 shares of the company’s stock worth $3,822,000 after acquiring an additional 12,631 shares in the last quarter. Finally, SCS Capital Management LLC boosted its holdings in AbbVie by 39.6% in the second quarter. SCS Capital Management LLC now owns 24,578 shares of the company’s stock worth $4,562,000 after acquiring an additional 6,978 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 0.0%

ABBV opened at $208.79 on Friday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a 50 day moving average of $221.58 and a two-hundred day moving average of $224.47. The firm has a market capitalization of $369.17 billion, a PE ratio of 88.47, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the firm earned $2.16 EPS. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Activity

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ABBV shares. Guggenheim restated a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Barclays assumed coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price for the company. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Morgan Stanley raised their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.